FluoGuide A/S (FRA:96X)
Germany · Delayed Price · Currency is EUR 3.160
-0.070 (-2.17%)
At close: Nov 28, 2025
FluoGuide Company Description
FluoGuide A/S, a clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark.
Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer.
The company has a collaboration agreement with ZEISS Medical Technologies for the development of FG001 for tumor imaging and surgical margins assessment for head and neck cancer.
FluoGuide A/S was incorporated in 2018 and is headquartered in Copenhagen, Denmark.
FluoGuide A/S
| Country | Denmark |
| Founded | 2018 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 8 |
| CEO | Morten Albrechtsen |
Contact Details
Address: Ole Maaløes Vej 3 Copenhagen, 2200 Denmark | |
| Phone | 45 31 22 66 60 |
| Website | fluoguide.com |
Stock Details
| Ticker Symbol | 96X |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Morten Albrechtsen | Chief Executive Officer |
| Ole Larsen | Chief Financial Officer |
| Donna Haire | Chief Operating Officer |